3PD - ALK and MET are synergistic co-activators of downstream signals by amplification in pulmonary sarcomatoid carcinoma: a potential for targeted therapy?

Date 27 March 2014
Event ELCC 2014
Session Poster Discussion 1
Topics Lung and other Thoracic Tumours
Pathology/Molecular Biology
Presenter Patrizia Gasparini
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors P. Gasparini1, G. Pelosi2, G. Sozzi3, V. Ciravolo3, S. Pupa3, E. Tamborini2, P. Scanagatta4, F. De Braud5, U. Pastorino4
  • 1Department Of Pathology And Experimental Oncology, Fondazione IRCCS Istituto tumori Milano, 20133 - Milano/IT
  • 2Department Of Pathology, Fondazione IRCCS Istituto tumori Milano, 20133 - Milano/IT
  • 3Department Of Experimental Oncology, Fondazione IRCCS Istituto tumori Milano, 20133 - Milano/IT
  • 4Department Of Thoracic Surgery, Fondazione IRCCS Istituto tumori Milano, 20133 - Milano/IT
  • 5Department Of Medical Oncology, Fondazione IRCCS Istituto tumori Milano, 20133 - Milano/IT

Abstract

Genetic alterations suitable for targeted therapy are poorly known issues in pulmonary sarcomatoid carcinoma (PSC), an uncommon and life-threatening family of non-small cell lung cancer (NSCLC). We here investigate the role of ALK and MET in this subtype of aggressive NSCLC.